MOMIPP
MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB) [1][2].
Product Specifications
CAS Number
1363421-46-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PIKfyve
Type
Reference compound
Related Pathways
PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/momipp.html
Purity
99.00
Solubility
DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(/C=C/C1=C(NC2=C1C=C(C=C2)OC)C)C3=CC=NC=C3
Molecular Formula
C18H16N2O2
Molecular Weight
292.33
Precautions
H302, H315, H319, H335
References & Citations
[1]Margaux Colin, et al. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide. Cancers (Basel) . 2019 Mar 22;11 (3) :411.|[2]Zehui Li, et al. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma. BMC Cancer. 2019 Jan 16;19 (1) :77.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TP303942M 100 µg
NCE2 (UBE2F) (NM_080678) Human Recombinant Protein
Sign In for Pricing
View Details 
BNC472550-500 1x 500 µL
NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details